Original Article

Economic Burden of HIV/AIDS in Iran: A Modelling Approach


Background: HIV/AIDS is a leading cause of mortality and morbidity in Low-and-Middle-Income-Countries (LMICs). It might potentially lead to an economic burden on the health system. There is no certainty about the prevalence of HIV/AIDS in Iran. Therefore, we aimed to estimate the cost of illness of HIV/AIDS in Iran.

Methods: We applied a societal perspective to capture the direct and indirect costs attributed to HIV/AIDS in Iran. We used data for age-standardized prevalence produced by the country HIV/AIDS Surveillance System for 2018. The study estimated both direct and indirect costs for a hypothetical cohort of the Iranian adult population (here equates to all registered cases with Surveillance System). For mitigating the uncertainty around the estimations, we have used an optimistic and pessimistic analysis.

Results: The base case scenario showed that total direct costs and indirect costs attributed to the HIV/AIDS were US$7,946,530 and US$ 1,288,586 at the end of 2018. Moreover, the total cost is 8,785,116 US$.

Conclusion: Direct costs have formed approximately 85% of total costs. The policymakers and planners should consider that these costs are only related to diagnosed or registered infected populations. These costs will be raised dramatically with increasing the diagnosed patients.


1. Gona PN, Gona CM, Ballout S, et al (2020). Burden and changes in HIV/AIDS morbidity and mortality in Southern Africa Development Community Countries, 1990–2017. BMC Public Health, 20(1):867.
2. Saeed SM, Ayuwat D (2020). A Qualitative Study of Stigma Experience by Households with People Living With HIV/AIDS in Kaduna State, Nigeria. Systematic Reviews in Pharmacy, 11:1320-1328.
3. Nketiah-Amponsah E, Abubakari M, Baffour PT (2019). Effect of HIV/AIDS on Economic Growth in Sub-Saharan Africa: Recent Evidence. Int Adv Econ Res, 25:469-480.
4. Frank TD, Carter A, Jahagirdar D, et al (2019). Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. The Lancet HIV, 6:e831-e859.
5. Jahagirdar D, Walters MK, Novotney A, et al (2021). Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. The Lancet HIV, 8:e633-e651.
6. SeyedAlinaghi S, Taj L, Mazaheri-Tehrani E, et al (2021). HIV in Iran: onset, responses, and future directions. AIDS, 35:529-542.
7. Control CfCD (2018). Latest statistics on HIV infection in Islamic Republic of Iran. Iran Ministry of Health Tehran.
8. Dzansi G, Tornu E, Chipps J (2020). Promoters and inhibitors of treatment adherence among HIV/AIDS patients receiving antiretroviral therapy in Ghana: Narratives from an underserved population. PloS One, 15:e0230159.
9. Prah J, Hayfron-Benjamin A, Abdulai M, Lasim O, Nartey Y (2018). Factors affecting adherence to antiretroviral therapy among HIV/AIDS patients in cape coast metropolis. Ghana J HIV AIDS, 4.
10. Ritchwood TD, Bishu KG, Egede LE (2017). Trends in healthcare expenditure among people living with HIV/AIDS in the United States: evidence from 10 Years of nationally representative data. Int J Equity Health, 16: 188.
11. Poudel AN, Newlands D, Simkhada P (2017). The economic burden of HIV/AIDS on individuals and households in Nepal: a quantitative study. BMC Health Services Research, 17(1):76.
12. Zhuang X, Chen Y, Wu Z, et al (2020). Analysis of hospitalization expenses of 610 HIV/AIDS patients in Nantong, China. BMC Health Serv Res, 20:1-813.
13. Bank W (2019). GDP per capita (current US$) - Iran, Islamic Rep. In: Bank W, Washington.
14. Assebe LF, Negussie EK, Jbaily A, Tolla MTT, Johansson KA (2020). Financial burden of HIV and TB among patients in Ethiopia: a cross-sectional survey. BMJ Open, 10:e036892.
15. de Siqueira-Filha NT, de Albuquerque MdFM, Rodrigues LC, Legood R, Santos AC (2018). Economic burden of HIV and TB/HIV coinfection in a middle-income country: a costing analysis alongside a pragmatic clinical trial in Brazil. Sex Transm Infect, 94:463-469.
16. Joulaei H, Lankarani KB, Kazerooni PA, Marzban M (2017). Number of HIV-infected cases in Iran: True or just an iceberg. Indian J Sex Transm Dis AIDS, 38:157-162.
17. Moradi G, Asadi H, Gouya MM, et al (2019). The communicable diseases surveillance system in Iran: challenges and opportunities. Arch Iran Med, 22:361-368.
18. Verbooy K, Wagener M, Kaddouri M, Roelofs P, Miedema H, van Gorp E, Brouwer W, van Exel J (2018). Are people living with HIV less productive at work? AIDS Care, 30:1265-1272.
IssueVol 52 No 2 (2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v52i2.11893
HIV/AIDS Antiretroviral therapy Cost of illness Economic burden

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Ghiasvand H, Shamseddin J, Naghdi S, Biglarian A. Economic Burden of HIV/AIDS in Iran: A Modelling Approach. Iran J Public Health. 2023;52(2):399-406.